Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer

Clinical Breast Cancer

Volumn 10, Issue 4, 2010, Pages 281-287

  Conlin, Alison ^a   Seidman, Andrew ^a   Bach, Ariadne ^a   Lake, Diana ^a   Dickler, Maura ^a   D'Andrea, Gabriella ^a   Traina, Tiffany ^a   Danso, Michael ^b   Brufsky, Adam ^c   Saleh, Mansoor ^d   Clawson, Alicia ^e   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Virginia Oncology Associates   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d Georgia Cancer Specialists   (United States)

^e Abraxis BioScience Inc   (United States)

Author keywords

Nab paclitaxel; Neutropenia; Platinum agents; Progression free survival

Indexed keywords

ALBUMIN; CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SYSTOLIC DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77955615612     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.036     Document Type: Article

References (21)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/proto-oncogene. Science 1987; 235:177-182
2. Press M F, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15:2894-2904
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792
4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726
5. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648
6. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase III trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor receptor positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4247-4250
7. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin human breast and ovarian cancer cells. Oncogene 1994; 9:1829-1838
8. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xeno-grafts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17:2235-2249
9. Arteaga CL, Winnier AR, Poirier MC, et al. p185c-erbB-2 signal enhances cispl-atin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994; 54:3758-3765
10. Baselga J, Seidman AD, Rosen P P, et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 1997; 11(suppl 2):43-48
11. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immuno-phenotype and gene amplification. J Clin Oncol 2001; 19:2587-2595
12. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-week paclitaxel for metastatic breast cancer, with trastu-zumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non-overexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol 2008; 26:1642-1649
13. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of pa-clitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in woman with HER2-overexpressing metastatic breast cancer: NCCTG Study 983252. Clin Breast Cancer 2005; 6:425-432
14. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803
15. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 22:3611-3619
16. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007; 60:759-766
17. Burris H, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22:1621-1629
18. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastu-zumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786-2792
19. Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of weekly pacli-taxel and carboplatin in patients with advanced breast cancer. J Clin Oncol 2002; 20:3857-3864
20. Pegram MD, Pienkowski T, Northfelt D W, et al. Results of two open-label, mul-ticenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96:759-769
21. Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without car-boplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25(34 suppl):18s (abstract LBA1008).